The present invention relates to a pharmaceutical antiretro viral composition comprising (i) a nucleoside reverse transcriptase inhibitor selected from lamivudine and emtricitabine (ii) extended release nevirapine and (iii) tenofovir a process for preparing such composition and the use of such composition in medicine particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.
